Star Surgical management expects Q4 China revenue growth as supply improves and V5 and torque mix rises, while lower unit costs and reduced tariffs support gross-margin recovery. A 20% adjusted EBITDA margin is viewed as achievable going forward.
STAA · Staar Surgical Co
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Star Surgical reported third-quarter net sales of $83.4 million, down 12% from the prior year but up 21% excluding $25.9 million of China deferred sales. Gross margin was 70.9%, and adjusted EBITDA was $14.4 million.
STAAR Surgical Company reported third-quarter net sales of $83.4 million, up 21% excluding the prior year's $25.9 million China shipment, while gross margin fell to 70.9% and net income was $5.6 million.
STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, down 12% from $94.7 million, as the prior-year quarter included $25.9 million of deferred China sales. Net income was $5.6 million, or $0.11 per diluted share, and cash, cash equivalents, and investments reached $206.4 million. The Board authorized a $50 million share repurchase program in September 2026.
STAAR Surgical Company appointed David Bailey as Chief Commercial Officer effective September 8, 2026; the amendment corrects his $850,000 initial equity award to 50% RSUs and 50% stock options, with a separate $1,400,000 award split equally.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. STAAR delivered record nine-month revenue and positive free cash flow, underlying quarterly sales growth of 21%, strong regional performance outside China, continued China share gains and progress on presbyopia and market access, supported by $206.4 million of cash and investments, no debt and a $50 million repurchase authorization. Risks include gross-margin and tariff pressure, elevated unit costs, insufficient China supply, regional weakness, sequentially lower fourth-quarter China revenue and withheld broader guidance.
- + Third-quarter net sales increased 21% to $83.4 million after excluding $25.9 million of deferred China sales recognized in the prior-year quarter. new
- − Reported third-quarter net sales declined 12% to $83.4 million because the prior-year quarter included $25.9 million of deferred China sales. new
- − Japan and South Korea declined year over year due to currency headwinds and overall market weakness. new
- − U.S.-origin China inventory remains exposed to tariffs despite the transition to Swiss manufacturing. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $20M | Q2 2026 | — |
| Adjusted EBITDA per diluted share non-GAAP | $0.39 | Q2 2026 | — |
| Americas sales growth Y/Y | 12% | Q2 2026 | — |
| APAC sales growth Y/Y | 189% | Q2 2026 | — |
| China sales | $52.3M | Q2 2026 | — |
| EMEA sales growth Y/Y | -1% | Q2 2026 | — |
| Global Sales Growth (Constant Currency) non-GAAP | 114.8% | Six Months Ended July 3, 2026 | — |
| Gross margin | 74.5% | Q2 2026 | — |
| Net sales excluding China | $41.2M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STAA
this stock
Staar Surgical Co
|
$1.27B | +9.8% | -23.7% | 2535.0 | 7.3% |
|
ISRG
Intuitive Surgical Inc
|
$145.92B | -25.7% | +20.5% | 51.0 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.86B | — | +8.2% | 95.6 | 3.0% |
|
MDLN
Medline Inc.
|
$51.51B | -6.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$36.15B | -4.5% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 24
Star Surgical management expects Q4 China revenue growth as supply improves and V5 and torque mix rises, while lower unit costs and reduced tariffs support gross-margin recovery. A 20% adjusted EBITDA margin is viewed as achievable going forward.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STAA | -5.0% | +17.3% | -15.2% | +3.3% | +9.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -1.1% | +22.9% | -11.7% | +6.7% | +2.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.